Preview. Site Selection for Life Sciences Companies: Cluster Report 2015
Venture Valuation presented a preview of its new report together with KPMG “Site Selection for […]
Biotech Product Valuation – Setting a Price for Acquisitions
Big acquisitions like the recent purchase by Roche, Switzerland of Intermune, USA or AbbVie‘s successful […]
How to raise sufficient funds for Biotechs?
September 2014: Financing is an ongoing challenge for all Biotech companies. Without sufficient resources, products […]
The premium of a big pharma license deal
Venture Valuation recently published an article in Nature Biotechnology 32, 617–619, (2014) based on data […]
Soccer and Pharma/BIOtech
Marketing alliances between well-known brand names and consumer products have long been a tradition for […]
Is Orphan saving Biotech?
Orphan drugs have been en vogue for a while. However, in the last quarter there […]
Who is investing and who is not?
Are you wondering what investors still have money and are investing? At Biotechgate we are […]
What is the impact of Novartis transformation on biotech industry?
With the announcement of the portfolio transformation of Novartis this month, we believe this will […]
Early stage VC funding in the US more difficult than ever
Even with the public biotech was just at an all time high, VCs in the […]
Global, Early-Stage Investors in Emerging Life Science Companies
Does it make sense for a life science fundraising executive in Europe to look internationally […]